<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03752723</url>
  </required_header>
  <id_info>
    <org_study_id>GX-I7-CA-006</org_study_id>
    <nct_id>NCT03752723</nct_id>
  </id_info>
  <brief_title>Study of GX-I7 in Combination With Pembrolizumab in Refractory or Relapsed (R/R) TNBC Subjects(GX-I7-CA-006/KEYNOTE-899)</brief_title>
  <official_title>A Phase 1b/2, Open Label, Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacodynamics and Antitumor Activity of GX-I7 in Combination With Pembrolizumab in Subjects With Refractory or Relapsed (R/R) TNBC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genexine, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Genexine, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and tolerability of escalating doses GX-I7 in combination with
      standard dose pembrolizumab, and to evaluate objective response rate (ORR) in subjects with
      refractory or relapsed TNBC
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 27, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and nature of DLTs</measure>
    <time_frame>during the first 5 weeks</time_frame>
    <description>To evaluate the safety and tolerability of GX-I7 in combination with standard dose pembrolizumab</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence, nature and severity of adverse events</measure>
    <time_frame>up to 24month</time_frame>
    <description>graded according to NCI CTCAE v5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>up to 24month</time_frame>
    <description>defined as percentage of subjects with a complete response (CR) or partial response (PR) per RECIST v.1.1</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">83</enrollment>
  <condition>Triple Negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>combination with CPA, GX-I7, and pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental: combination
Assigned interventions: CPA, GX-I7 and pembrolizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>combination with GX-I7, and pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental: combination
Assigned interventions: GX-I7 and pembrolizumab (without CPA)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GX-I7</intervention_name>
    <description>i.m.</description>
    <arm_group_label>combination with CPA, GX-I7, and pembrolizumab</arm_group_label>
    <arm_group_label>combination with GX-I7, and pembrolizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>i.v.</description>
    <arm_group_label>combination with CPA, GX-I7, and pembrolizumab</arm_group_label>
    <arm_group_label>combination with GX-I7, and pembrolizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>i.v.</description>
    <arm_group_label>combination with CPA, GX-I7, and pembrolizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Triple negative must be defined as guidelines of American Society of Clinical
             Oncology(ASCO)/ College of American Pathologist(CAP): Estrogen Receptor (ER) &lt; 1%
             positive tumor nuclei, Progesterone Receptor (PR) &lt; 1% positive tumor nuclei, and
             negative for HER2 by IHC 1+, 0 or negativity status confirmed by in situ hybridization
             (ISH).

          2. Subject must have received anthracycline and taxane based chemotherapy for TNBC

          3. Has measurable disease as defined by RECIST 1.1 as assessed by the the local site
             Investigator/radiology.

          4. Female subjects, age ≥ 19 years at the time of consent.

        Key Exclusion Criteria:

          1. Known severe hypersensitivity (≥ Grade 3) to pembrolizumab, pembrolizumab formulation
             excipients or GX-I7 formulation excipients or cyclophosphamide formulation.

          2. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with
             an agent directed to another co-inhibitory T-cell receptor (ie, CTLA-4, OX-40, CD137)
             or has previously participated in a Merck pembrolizumab (MK-3475) clinical trial.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Minkyu Heo</last_name>
    <phone>+82 31 628 3340</phone>
    <email>mkheo@genexine.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JeeHyun Kim, MD</last_name>
      <email>jhkimmd@snu.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ajou Medical Center</name>
      <address>
        <city>Suwon-si</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Goyang-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keun Seok Lee, MD</last_name>
      <email>kslee@ncc.re.kr</email>
    </contact>
    <investigator>
      <last_name>Keun Seok Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Medical Center</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hee Kyung Ahn, MD</last_name>
      <email>hkahn.onco@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Hee Kyung Ahn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SungBae Kim, MD</last_name>
      <email>sbkim3@amc.seoul.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ewha Womans University Mokdong Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyoung Eun Lee, MD</last_name>
      <email>oncolee@ewha.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JeeHung Kim, MD</last_name>
      <email>OK8504@yuhs.ac</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyong Hwa Park, MD</last_name>
      <email>khpark@korea.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Kyong Hwa Park, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>YoungHyuck Im, MD</last_name>
      <email>yh00.im@samsung.com</email>
    </contact>
    <investigator>
      <last_name>YoungHyuck Im, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul ST.Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JiEun Lee, MD</last_name>
      <email>befamiliar@catholic.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joohyuk Sohn, MD</last_name>
      <email>ONCOSOHN@yuhs.ac</email>
    </contact>
    <investigator>
      <last_name>Joohyuk Sohn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>November 19, 2018</study_first_submitted>
  <study_first_submitted_qc>November 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 26, 2018</study_first_posted>
  <last_update_submitted>March 30, 2020</last_update_submitted>
  <last_update_submitted_qc>March 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>TNBC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

